Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Ho

Showing results (131-140 of 241) with videos related to

Pageof 25
Sort By:
Journal of Medical Virology|March 11, 2024
Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball AssociationCaroline G Tai, Miriam J Haviland, Steven M Kissler, et al.
Research Square|November 21, 2023
Allosteric Neutralization by Human H7N9 AntibodiesManxue Jia, Hanjun Zhao, Nicholas C Morano, et al.
Nature Communications|May 27, 2024
Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin headManxue Jia, Hanjun Zhao, Nicholas C Morano, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Distinct allosteric remodeling of HIV-1 Env dynamics on virions by gp41-directed antibodies reveals two modes of neutralizationWang Xu, Narendra Kumar Gonepudi, Junyu Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2003
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4Theresa L-Y Chang, Chia-Hwa Chang, David A Simpson, et al.
The Journal of Infectious Diseases|August 27, 2002
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccinationMartin Markowitz, Xia Jin, Arlene Hurley, et al.
Cell Reports|October 15, 2025
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariantsIan A Mellis, Madeline Wu, Hsiang Hong, et al.
Cell Reports|November 26, 2025
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariantsIan A Mellis, Madeline Wu, Hsiang Hong, et al.
Journal of Virology|February 15, 2005
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding regionZhiwei Chen, Linqi Zhang, Chuan Qin, et al.
Cell Reports|October 27, 2021
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domainGabriele Cerutti, Yicheng Guo, Pengfei Wang, et al.
Pageof 25

Showing results (131-140 of 241) with videos related to

Sort By:
Pageof 25
Journal of Medical Virology|March 11, 2024
Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball AssociationCaroline G Tai, Miriam J Haviland, Steven M Kissler, et al.
Research Square|November 21, 2023
Allosteric Neutralization by Human H7N9 AntibodiesManxue Jia, Hanjun Zhao, Nicholas C Morano, et al.
Nature Communications|May 27, 2024
Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin headManxue Jia, Hanjun Zhao, Nicholas C Morano, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Distinct allosteric remodeling of HIV-1 Env dynamics on virions by gp41-directed antibodies reveals two modes of neutralizationWang Xu, Narendra Kumar Gonepudi, Junyu Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2003
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4Theresa L-Y Chang, Chia-Hwa Chang, David A Simpson, et al.
The Journal of Infectious Diseases|August 27, 2002
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccinationMartin Markowitz, Xia Jin, Arlene Hurley, et al.
Cell Reports|October 15, 2025
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariantsIan A Mellis, Madeline Wu, Hsiang Hong, et al.
Cell Reports|November 26, 2025
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariantsIan A Mellis, Madeline Wu, Hsiang Hong, et al.
Journal of Virology|February 15, 2005
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding regionZhiwei Chen, Linqi Zhang, Chuan Qin, et al.
Cell Reports|October 27, 2021
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domainGabriele Cerutti, Yicheng Guo, Pengfei Wang, et al.
Pageof 25